Herpes simplex virus gene therapy for dystrophic epidermolysis bullosa (DEB).
Epstein AL, Haag-Molkenteller C.
Cell. 2023 Aug 17;186(17):3523-3523.e1. doi: 10.1016/j.cell.2023.07.031.
Erythema Multiforme: Recognition and Management.
Trayes KP, Love G, Studdiford JS.
Am Fam Physician. 2019 Jul 15;100(2):82-88.
Ramsay Hunt Syndrome: An Introduction, Signs and Symptoms, and Treatment.
Goswami Y, Gaurkar SS.
Cureus. 2023 Jan 12;15(1):e33688. doi: 10.7759/cureus.33688. eCollection 2023 Jan.
Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa.
Guide SV, Gonzalez ME, Bağcı IS, Agostini B, Chen H, Feeney G, Steimer M, Kapadia B, Sridhar K, Quesada Sanchez L, Gonzalez F, Van Ligten M, Parry TJ, Chitra S, Kammerman LA, Krishnan S, Marinkovich MP.
N Engl J Med. 2022 Dec 15;387(24):2211-2219. doi: 10.1056/NEJMoa2206663.
Pemphigus vulgaris and herpes simplex virus: Imperfect together.
Heymann WR.
J Am Acad Dermatol. 2023 Mar;88(3):549-550. doi: 10.1016/j.jaad.2023.01.018. Epub 2023 Jan 28.
Recent Updates in the Treatment of Erythema Multiforme.
Soares A, Sokumbi O.
Medicina (Kaunas). 2021 Sep 1;57(9):921. doi: 10.3390/medicina57090921.
Erythema multiforme, Stevens-Johnson syndrome/toxic epidermal necrolysis - diagnosis and treatment.
Grünwald P, Mockenhaupt M, Panzer R, Emmert S.
J Dtsch Dermatol Ges. 2020 Jun;18(6):547-553. doi: 10.1111/ddg.14118. Epub 2020 May 29.
In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial.
Gurevich I, Agarwal P, Zhang P, Dolorito JA, Oliver S, Liu H, Reitze N, Sarma N, Bagci IS, Sridhar K, Kakarla V, Yenamandra VK, O'Malley M, Prisco M, Tufa SF, Keene DR, South AP, Krishnan SM, Marinkovich MP.
Nat Med. 2022 Apr;28(4):780-788. doi: 10.1038/s41591-022-01737-y. Epub 2022 Mar 28.
Practical considerations relevant to treatment with the gene therapy beremagene geperpavec-svdt for dystrophic epidermolysis bullosa.
Paller AS, Guide SV, Ayala D, Gonzalez ME, Lucky AW, Bagci IS, Marinkovich MP.
J Dermatolog Treat. 2024 Dec;35(1):2350232. doi: 10.1080/09546634.2024.2350232. Epub 2024 May 9.
Rapid identification of primary atopic disorders (PAD) by a clinical landmark-guided, upfront use of genomic sequencing.
Niehues T, von Hardenberg S, Velleuer E.
Allergol Select. 2024 Oct 2;8:304-323. doi: 10.5414/ALX02520E. eCollection 2024.
